

## INTERNATIONAL OBSERVATIONAL

POST-COMMERCIALIZATION STUDY

### PHASE IV

**21**  
countries

**4230**  
patients

Treatment:  
2 to 3 months



To assess  
the **efficacy and tolerance**  
of Cleanance Comedomed,  
for patients  
**suffering from acne**  
from almost no lesions  
to moderate severity

FIRST-LINE TREATMENT

FOLLOW-UP ON CARE

QUALITY OF LIFE

# Cleanance Comedomed

Alone | In association | In relay



EAU THERMALE  
**Avène**  
LABORATOIRE DERMATOLOGIQUE

EFFICACY — TOLERANCE — QUALITY OF LIFE

Efficacy  
on facial acne

**-36.4%**

Decrease mean GEA score\*

Efficacy  
on acne lesions

**80.2%**

perceived  
by the doctors


Tolerance  
overall  
assessment

**94.7%**

Significant  
improvement  
of Quality of Life

**-44.2%**

Decrease on CADI score \*\*



N°Obs RV3278A/ET0943 2019 01

\*Dreno B, Poli F, Pawin H, Beylot C, Faure M, Chivot M, Auffret N, Moysse D, Ballanger F, Revuz A. Development and evaluation of a Global Acne Severity Scale (GEA Scale) suitable for France and Europe. J EADV 2011; 25:43-48.

\*\*Dreno B, Finley A, Nocera T, Verrière F, Taieb C, Myon E. The Cardiff Acne Disability Index. Dermatology 2004; 208:104-8.